HOOKIPA Pharma Inc. (HOOK) Reports Promising Anti-Tumor Activity & Favorable Tolerability for Phase 1 Monotherapy Data of HB-201 for Treatment of Advanced HPV16+ Cancers

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/1/2026

1. NKE
2. TSLA
3. BE
4. NVDA
5. KKR
6. GOOGL
7. TALO
8. PB
9. GIS
10. SPCX

Go back to HOOKIPA Pharma Inc. (HOOK) Reports Promising Anti-Tumor Activity & Favorable Tolerability for Phase 1 Monotherapy Data of HB-201 for Treatment of Advanced HPV16+ Cancers

HOOKIPA Pharma Inc. (HOOK) Prices 3.4M Share Common Offering at $11.75/Sh

December 9, 2020 6:14 AM EST

HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the pricing of an underwritten public offering of 3,400,000 shares of its common stock and 2,978 shares of its Series A convertible preferred stock (the Offering). The public offering price of each share of common stock is $11.75... More